Titlebook: Radiopharmaceutical Therapy; Lisa Bodei,Jason S. Lewis,Brian M. Zeglis Book 2023 The Editor(s) (if applicable) and The Author(s), under ex

车床

Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutch as .Lu-labeled agonists of somatostatin receptor subtype 2 (SST.) (e.g., [.Lu]Lu-DOTA-TOC and [.Lu]Lu-DOTA-TATE (Lutathera.)). SST. are highly overexpressed in neuroendocrine tumors (NETs), which are most commonly found in the stomach, intestines, pancreas, and lungs. Until recently, it was thoug

节约

Small Molecules as Vectors for Radiopharmaceutical Therapyth metastatic, castration-resistant prostate cancer whose tumors express prostate-specific membrane antigen (PSMA; [.Lu]Lu-PSMA-617), and patients with metastatic or unresectable neuroblastoma, pheochromocytoma, or paraganglioma ([.I]MIBG). Numerous lines of inquiry continue to be pursued with small

PHON

不公开

chalice

The Nuclear Chemistry of Therapeutic Radionuclides transformation processes and can be helpful for the molecular imaging of radionuclides and the radiotherapeutics carrying them. Next, the most relevant (and some potential) therapeutic radionuclides are identified. Finally, the chapter evaluates the relevant production pathways of therapeutic radionuclides.

interference

The Radiobiology of Radiopharmaceutical Therapy: The Input of Imaging and Radiomics of radiobiology should no longer be restricted to preclinical experiments and should be extended to clinical research. The implementation of clinical radiobiology requires the analysis of patient samples and the use of non-invasive imaging approaches to extract tumour features that are indicative of response to RPT.

cyanosis

forthy

Antibodies as Vectors for Radiopharmaceutical Therapy of the results for each of the steps. At the end of this chapter, those studying RPT should have a good understanding of the strengths and limitations of radioimmunoconjugates as therapeutic tools in the clinic.

cultivated

Introduction: The Case for Radiopharmaceutical Therapyelopment of new approaches to RPT is possible with new targets and the application of novel radionuclides. In the end, the forward progress of RPT is predicated on both well-designed, step-wise, multicenter prospective clinical trials and specialized endoradiotherapy training programs.

dictator

Dosimetry in Radiopharmaceutical Therapythis multifactorial paradigm is encapsulated in the field of internal dosimetry. Through dosimetry, we quantify the distribution and strength of the intervention in terms of radiation dose deposition. This information supports clinicians in predicting and optimizing treatment outcomes.